Rituximab Treatment for the Patient with Refractory Lupus Nephritis / 대한류마티스학회지
The Journal of the Korean Rheumatism Association
;
: 251-262, 2005.
Article
in Korean
| WPRIM
| ID: wpr-171472
ABSTRACT
OBJECTIVE:
To determine preliminary evidence for the safety and efficacy of B lymphocyte depletion therapy in refractory systemic lupus erythematosus (SLE).METHODS:
Four female lupus nephritis patients who had been refractory to steroid and one or more immunosuppressive therapy were treated on an open-label basis. During a 4-week period, each patient received two 500-mg infusions of rituximab and two 750-mg infusions of cyclophosphamide.RESULTS:
Patient 1, 2, and 3 were responded with rituximab treatment with improvements in SLEDAI and laboratory parameters such as C3/C4 and 24 hour urine protein. However, patient 4 had not improved with rituximab. The variation in the level of anti-double-stranded DNA antibody was different in individual patients. No significant adverse events were observed during follow-up.CONCLUSION:
This study provides an evidence for the safety and possible efficacy of B lymphocyte depletion therapy in refractory lupus nephritis. However a further randomized trial is needed to confirm the efficacy and durability of remission.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Lupus Nephritis
/
DNA
/
Follow-Up Studies
/
Lymphocyte Depletion
/
Cyclophosphamide
/
Rituximab
/
Lupus Erythematosus, Systemic
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
Limits:
Female
/
Humans
Language:
Korean
Journal:
The Journal of the Korean Rheumatism Association
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS